[Effect of phenformin and miscleron on the blood somatomedin activity level in breast cancer].
It was shown that in patients with breast cancer and cancer of the corpus uteri in the presence of hypercholesterinemia and hypertriglyceridemia the level of blood somatomedin activity would be 3--5 times the control values, being 3.04 +/- 0.73% unit/ml in breast cancer patients and 2.20 +/- 0.61 unit/ml in those with endometrial cancer. An antidiabetic drug phenformin (50--100 mg/day) as well as an antidiabetic drug miscleron (1--1.5 g/day), used during 7--24 weeks, were found to result in the reduced level of the somatomedin activity in breast cancer patients being in the stage of remission (1.94 +/- 0.36 unit/ml before the treatment, 0.94 +/- 0.17 unit/ml after it).
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002994:Clofibrate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use*; D013002:Somatomedins / Q000097:blood*; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy
D013002:Somatomedins; D010629:Phenformin; D002994:Clofibrate
Vliianie fenformina i misklerona na uroven' somatomedinovoĭ aktivnosti krovi u bol'nykh rakom molochnoĭ zhelezy.